Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer

Kelly, William Kevin; Curley, Tracy; Slovin, Susan F.; Heller, Glenn; McCaffrey, John; Bajorin, Dean F.; Ciolino, Allison; Regan, Kevin; Schwartz, Morton K.; George, Daniel J.; Oh, William; Smith, Matthew R.; Kaufman, Donald S.; Small, Eric J.; Schwartz, Lawrence H.; Larson, S. M.; Tong, William P.; Scher, Howard I.

doi:10.1200/jco.2001.19.1.44

Cited by 172 publications

(86 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The median survival of our study population (13+ months) was slightly better than that found in most series (8 -10 months) treated with other cytotoxic drugs or placebo (Tannock et al, 1996;Heidenreich et al, 2001;Kelly et al, 2001). Although ours was not a randomised trial, it is possible that an active and safe chemotherapy such as weekly epirubicin may prolong survival with a relatively good quality of life in HRPC patients.…”

Section: Discussioncontrasting

confidence: 52%

“…More recently, taxanes and new drug combinations have demonstrated some activity in this disease, partially due to a reconsideration of end points such as QL parameters (Tannock et al, 1996;Picus and Schultz, 1999;Kelly et al, 2001). The results of this study provide evidence of the palliative effect of weekly epirubicin chemotherapy in 131 evaluable patients with HRPC.…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

Weekly epirubicin in patients with hormone-resistant prostate cancer

et al. 2002

View full text Add to dashboard Cite

The aim of this study was to investigate the benefit of weekly epirubicin in the treatment of metastatic hormone-resistant prostate cancer. One hundred and forty-eight patients with metastatic hormone-resistant prostate cancer received weekly 30-min intravenous infusions of epirubicin 30 mg m 2 of body surface area. The primary end-point was palliative response, defined as a reduction in pain intensity and an improvement in performance status. The secondary end-points were the duration of the palliative response, quality of life and survival. Fifty-seven (44%) of the 131 evaluable patients met the primary criterion of palliative response after six treatment cycles and 73 (56%) after 12 cycles; the median duration of the response was 9 months (range 1 -11). The median global quality of life improved in 52% of the patients after six cycles and in 68% after 12 cycles. The 12-and 18-month survival rates were respectively 56 and 31%, with a median survival of 13+ months (range 1 -36). The treatment was well tolerated: grade 3 neutropenia was observed in 8% of the patients, grade 3 anaemia in 7%, and grade 3 thrombocytopenia in 3%. None of the patients developed grade 4 toxicity or congestive heart failure. Weekly epirubicin chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on the quality of life and survival.

show abstract

Section: Discussioncontrasting

confidence: 52%

Section: Discussionmentioning

confidence: 85%

Weekly epirubicin in patients with hormone-resistant prostate cancer

et al. 2002

View full text Add to dashboard Cite

show abstract

“…5,6 Short-lived prostate-specific antigen (PSA) responses are seen with prednisolone, estramustine and diethylstilboestrol, but these last two drugs are associated with significant thrombo-embolic toxicity. 7 Most patients remain asymptomatic for some months following detection of PSA rise after androgen withdrawal, so there is a clear need for a well tolerated, orally administered, disease-modifying therapy.…”

Section: Introductionmentioning

confidence: 99%

Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer

Spicer

Plunkett

Somaiah

et al. 2005

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

“…Results have been encouraging in Phase II trials, with PSA declines 50% in 60% to 100% of patients and objective response rates from 45% to 65% in the subset of patients with measurable dis- ease. 34,36,[92][93][94][95] The measurable response rate gives a further indication that carboplatin may have a role in the front-line management of certain patients with HRPC. Of course, care in interpreting these trials is needed, because these were small Phase II trials with highly selected patients, many of whom had a good performance status.…”

Section: Multiagent Regimens That Include Cisplatin and Carboplatinmentioning

confidence: 99%

Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?

Tay

Huang

2006

Cancer

View full text Add to dashboard Cite

Docetaxel chemotherapy is the current standard of care for metastatic hormone-refractory prostate cancer (HRPC). Platinum chemotherapy drugs, such as cisplatin and carboplatin, have moderate single-agent activity in HRPC. Next-generation platinum drugs, including satraplatin and oxaliplatin, may have additional activity in the management of HRPC. Furthermore, neuroendocrine differentiation may play a role in disease progression, providing a rationale for platinum-based chemotherapy in the management of HRPC. The authors reviewed the MEDLINE database for reports related to platinum-based chemotherapy in patients with advanced prostate cancer and evaluated studies that reviewed the role of neuroendocrine differentiation in the progression of HRPC. Older studies from the 1970s and 1980s suggested a lack of activity of cisplatin and carboplatin; however, those studies were flawed at least in part by their methods of response assessment. More recent Phase II studies of carboplatin suggested a moderate level of clinical and palliative activity when it was used as a single agent. However, when carboplatin was combined with a taxane and estramustine, high response rates were observed in several recent clinical trials. In addition, a randomized trial suggested that satraplatin plus prednisone improved progression-free survival compared with prednisone alone. For patients who progressed after docetaxel, no standard options existed in the literature that was reviewed. Several preliminary reports suggested that carboplatin and oxaliplatin may have activity as second-line chemotherapy. Platinum chemotherapy drugs historically have been considered inactive in HRPC, although a review of the data suggested otherwise. Carboplatin, in particular, induced very high response rates when it was combined with estramustine and a taxane, but it also appeared to have activity in patients who progressed after docetaxel. Satraplatin plus prednisone is being investigated in a large Phase III trial as second-line chemotherapy for HRPC. Targeting neuroendocrine cells may provide a new therapeutic approach to HRPC.

show abstract

Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer

Abstract: TEC has significant antitumor activity and is well tolerated in patients with progressive androgen-independent prostate cancer.

Cited by 172 publications

References 21 publications

Weekly epirubicin in patients with hormone-resistant prostate cancer

Weekly epirubicin in patients with hormone-resistant prostate cancer

Phase II study of oral capecitabine in patients with hormone-refractory prostate cancer

Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer?

Contact Info

Product

Resources

About